Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Janssen’s Simeprevir May Require Hep C Subpopulation Screening

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA advisory committee briefing documents recommend patients be screened for the Q80K polymorphism because of lower efficacy in those patients, an issue not seen with Incivek or Victrelis.


Related Content

Janssen Persuades Advisory Committee That Simeprevir Doesn’t Need Contraindication
Is It A Rash Or Photosensitivity? FDA May Have To Distinguish Them In Simeprevir Label
FDA AdComm Prep For Gilead’s Sofosbuvir Shows Agency Thinking On HCV Dosing
FDA Must Decide How To Handle Subgroups In Labeling For Boceprevir, Telaprevir


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts